BIOLASE (NASDAQ:BIOL) Now Covered by Analysts at StockNews.com

StockNews.com initiated coverage on shares of BIOLASE (NASDAQ:BIOL) in a research report released on Thursday morning. The firm issued a sell rating on the medical technology company’s stock.

Several other research firms have also recently commented on BIOL. Ascendiant Capital Markets lowered their target price on BIOLASE from $3.50 to $2.00 and set a “buy” rating for the company in a research note on Tuesday, September 3rd. Benchmark reiterated a “speculative buy” rating and issued a $0.40 price objective on shares of BIOLASE in a research report on Wednesday, October 2nd.

BIOLASE Price Performance

BIOL opened at $0.02 on Thursday. The stock has a market capitalization of $581,281.80, a P/E ratio of 0.00 and a beta of 0.67. The company’s 50 day simple moving average is $0.02 and its 200-day simple moving average is $0.07. BIOLASE has a one year low of $0.02 and a one year high of $1.94.

Institutional Inflows and Outflows

An institutional investor recently raised its position in BIOLASE stock. Virtu Financial LLC boosted its stake in BIOLASE, Inc. (NASDAQ:BIOL) by 1,068.0% in the first quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 143,537 shares of the medical technology company’s stock after purchasing an additional 131,248 shares during the quarter. Virtu Financial LLC owned about 0.43% of BIOLASE worth $27,000 as of its most recent SEC filing. 8.79% of the stock is currently owned by institutional investors.

BIOLASE Company Profile

BIOLASE, Inc, together with its subsidiaries, develops, manufactures, markets, and sells laser systems for dental practitioners and their patients in the United States and internationally. Its dental laser systems allow dentists, periodontists, endodontists, pediatric dentists, oral surgeons, and other dental specialists to perform a range of minimally invasive dental procedures, including cosmetic, restorative, and complex surgical applications.